<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of ovulation induction</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of ovulation induction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of ovulation induction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bart CJM Fauser, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Crowley, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ovulatory disorders can be identified in 18 to 25 percent of couples presenting with infertility [<a href="#rid1">1</a>]. Most of these women have oligomenorrhea, arbitrarily defined as menstruation that occurs at intervals of 35 days to six months. While ovulation may occasionally occur, spontaneous conception is unlikely.</p><p>This topic will review the efficacy of the different regimens used for ovulation induction in women with ovulatory disorders (<a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, gonadotropins, pulsatile gonadotropin-releasing hormone [GnRH] therapy, aromatase inhibitors, and dopamine agonists) and provide our approach to the management of such women. Some of these drugs are reviewed in greater detail elsewhere, and ovarian stimulation for assisted reproductive technologies (ART) is also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7400.html" rel="external">"Ovulation induction with clomiphene citrate"</a> and  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a> and  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">WOMEN WITH ANOVULATORY INFERTILITY</span><span class="headingEndMark"> — </span>The clinical approach to ovulation induction requires an understanding of the causes of anovulation. Proper diagnosis of underlying conditions may not only be relevant for infertility treatment but may also have general health implications (such as bone health, brain health and wellbeing, sexual health, and long-term cardiometabolic health). </p><p>The four most common ovulatory disorders include polycystic ovary syndrome (PCOS), hypogonadotropic hypogonadism (HA), primary ovarian insufficiency (POI), and hyperprolactinemia (see  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a>). Most experts have moved away from the World Health Organization (WHO) terminology which assign women to three categories of anovulation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>WHO class 1</strong> – Hypogonadotropic hypogonadal anovulation (hypothalamic amenorrhea [HA]) (see  <a class="medical medical_review" href="/d/html/7402.html" rel="external">"Evaluation and management of secondary amenorrhea"</a> and  <a class="medical medical_review" href="/d/html/7393.html" rel="external">"Functional hypothalamic amenorrhea: Pathophysiology and clinical manifestations"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>WHO class 2</strong> – Normogonadotropic normoestrogenic anovulation (almost all women in this category have polycystic ovary syndrome [PCOS]), when using the Rotterdam criteria for the diagnosis of PCOS [<a href="#rid2">2</a>]. This is the most common cause of anovulation. (see  <a class="medical medical_review" href="/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults", section on 'Diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>WHO class 3</strong> – Hypergonadotropic hypoestrogenic anovulation (primary ovarian insufficiency [POI; premature ovarian failure]) (see  <a class="medical medical_review" href="/d/html/7443.html" rel="external">"Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)"</a> and  <a class="medical medical_review" href="/d/html/7435.html" rel="external">"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)"</a>)</p><p></p><p>Hyperprolactinemia did not have a separate WHO category. The use of serum anti-müllerian hormone (AMH) concentrations may help to further define various patient categories. AMH levels are increased in PCOS and decreased in WHO class 1 and 3.</p><p class="headingAnchor" id="H3"><span class="h2">Hypogonadotropic hypogonadism</span><span class="headingEndMark"> — </span>Hypothalamic causes of hypogonadotropic hypogonadism include functional hypothalamic amenorrhea (FHA) and isolated gonadotropin-releasing hormone (GnRH) deficiency. Multiple factors may contribute to the pathogenesis of FHA, including eating disorders (such as anorexia nervosa), exercise, and stress. Women in this group, which accounts for 5 to 10 percent of anovulatory women, usually have amenorrhea (although a range of menstrual dysfunction can be seen) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/7393.html" rel="external">"Functional hypothalamic amenorrhea: Pathophysiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/104135.html" rel="external">"Epidemiology and causes of secondary amenorrhea"</a>.)</p><p>Biochemical findings include low serum estradiol concentrations and low or low-normal serum follicle-stimulating hormone (FSH) concentrations due to presumed decreased hypothalamic secretion of GnRH. AMH levels are low to normal under these circumstances. Reversing the lifestyle factors that contribute to the anovulation (low weight, excessive exercise, essentially any condition that leads to energy deficiency) should be attempted before considering ovulation induction with medications. (See  <a class="medical medical_review" href="/d/html/7393.html" rel="external">"Functional hypothalamic amenorrhea: Pathophysiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/104135.html" rel="external">"Epidemiology and causes of secondary amenorrhea"</a>.)</p><p>Although rare, hypogonadotropic hypogonadism presenting as primary amenorrhea can be due to complete congenital GnRH deficiency. This syndrome is called idiopathic hypogonadotropic hypogonadism or, if it is associated with anosmia, Kallmann syndrome. (See  <a class="medical medical_review" href="/d/html/7465.html" rel="external">"Isolated gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)"</a>.)</p><p>Many infiltrative diseases and tumors of the hypothalamus and pituitary can also result in hypogonadotropic hypogonadism (due to diminished GnRH release or gonadotropin deficiency). (See  <a class="medical medical_review" href="/d/html/104218.html" rel="external">"Causes of primary amenorrhea"</a> and  <a class="medical medical_review" href="/d/html/104135.html" rel="external">"Epidemiology and causes of secondary amenorrhea"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Polycystic ovary syndrome</span><span class="headingEndMark"> — </span>Women with PCOS constitute the largest group of anovulatory women encountered in clinical practice (70 to 85 percent of cases). Serum estradiol and FSH concentrations levels are normal, whereas luteinizing hormone (LH) concentrations may either be normal or elevated [<a href="#rid4">4</a>]. The criteria for diagnosis have been referred to as the "Rotterdam criteria"  (<a class="graphic graphic_table graphicRef54308" href="/d/graphic/54308.html" rel="external">table 1</a>) [<a href="#rid5">5</a>]. Other criteria have also been described. (See  <a class="medical medical_review" href="/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults", section on 'Diagnosis'</a>.)</p><p>In women with obesity and PCOS, weight loss, which may restore spontaneous ovulation in many women, should be attempted before treatment with ovulation induction agents is considered [<a href="#rid6">6</a>]. In addition, women with PCOS should be screened for impaired glucose tolerance before starting ovulation induction because of the associated risk of pregnancy complications [<a href="#rid7">7,8</a>], suboptimal perinatal outcomes [<a href="#rid9">9</a>], and affected cardiometabolic child health [<a href="#rid10">10</a>]. (see  <a class="medical medical_review" href="/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults"</a> and  <a class="medical medical_review" href="/d/html/4806.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Obstetric issues and management"</a>) </p><p>There are differing opinions regarding the use of ovulation induction versus assisted reproductive technologies (ART) for the treatment of infertile women with PCOS [<a href="#rid11">11</a>]. Theoretical reasons to use in vitro fertilization (IVF) as first-line therapy include the ability to freeze all embryos and perform single embryo transfer, thereby reducing the major complications of infertility treatment: multiple pregnancies and ovarian hyperstimulation syndrome (OHSS). However, there is little evidence available to support this approach.</p><p class="headingAnchor" id="H5"><span class="h2">Primary ovarian insufficiency</span><span class="headingEndMark"> — </span>POI, formerly referred to premature ovarian failure (POF) and defined as menopause before age 40 years, occurs in only 1 percent of all women but accounts for 5 to 10 percent of cases of anovulation. In most cases, the follicle pool is exhausted due to accelerated follicle loss of unknown origin  (<a class="graphic graphic_table graphicRef74029" href="/d/graphic/74029.html" rel="external">table 2</a>) [<a href="#rid12">12</a>]. Many strategies, including pretreatment suppression with exogenous estrogen, GnRH agonists, or androgens, have been proposed with the aim of improving outcomes from ovulation induction, but none have been successful. An experimental approach with as yet uncertain benefits include the in vitro activation (IVA) of the patient's own ovarian tissue/oocytes [<a href="#rid13">13</a>]. The only effective option is IVF with donor oocytes. (See  <a class="medical medical_review" href="/d/html/7435.html" rel="external">"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)"</a> and  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)"</a> and  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'</a>.)</p><p>Women with POI have other important health issues related to their estrogen deficiency, including an increased risk of osteoporosis and cardiovascular disease if estrogen is not replaced. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)", section on 'Importance of estrogen therapy'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Hyperprolactinemic anovulation</span><span class="headingEndMark"> — </span>Hyperprolactinemia accounts for 5 to 10 percent of women with anovulation. These women are anovulatory because hyperprolactinemia inhibits gonadotropin secretion, presumably by inhibiting GnRH. Most have oligomenorrhea or amenorrhea. Their serum gonadotropin concentrations are usually normal or decreased. (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a>.)</p><p>The presence of hyperprolactinemia should always be confirmed by several measurements of serum prolactin. Magnetic resonance imaging (MRI) of the head should be done in any woman with hyperprolactinemia in whom the cause is not obvious (eg, neuroleptic drug therapy, primary hypothyroidism). (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a>.)</p><p class="headingAnchor" id="H523299825"><span class="h1">OVERVIEW OF APPROACH</span></p><p class="headingAnchor" id="H4101037619"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The overarching goals of ovulation induction in women with anovulatory infertility are:</p><p class="bulletIndent1"><span class="glyph">●</span>Induce monofollicular rather than multifollicular development and subsequent mono-ovulation and, ultimately, a singleton pregnancy and birth of a healthy newborn  (<a class="graphic graphic_figure graphicRef61116" href="/d/graphic/61116.html" rel="external">figure 1</a>). Focus on cumulative outcomes over a given period of time, rather than per cycle outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Start with the least invasive, simplest, and cheapest treatment option; subsequent options should depend upon ovarian response (ovulation and number of follicles)  (<a class="graphic graphic_table graphicRef56718" href="/d/graphic/56718.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maximize the rate of singleton pregnancies, minimize multiple gestation rates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Minimize the risk of ovarian hyperstimulation syndrome (OHSS) in women undergoing gonadotropin therapy, particularly those with polycystic ovary syndrome (PCOS), who are at higher risk. This could mean canceling the cycle and refraining from intercourse in case of multiple follicle development. (See  <a class="medical medical_review" href="/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome", section on 'Prevention of OHSS'</a>.)</p><p></p><p class="headingAnchor" id="H3475154786"><span class="h2">General principles</span></p><p class="bulletIndent1"><span class="glyph">●</span>The method of ovulation induction selected by the clinician should be based upon the underlying cause of anovulation and the efficacy, costs, risks, patient burden, and potential complications associated with each method as they apply to the individual woman.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with ovulatory disorders should undergo conventional ovulation induction strategies before considering assisted reproductive technologies (ART) because success rates are good, and if monitored by an experienced clinician, complication rates are low [<a href="#rid14">14-16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Induction of ovulation should be differentiated from stimulation of multiple follicle development in ovulatory women (currently referred to as ovarian stimulation [<a href="#rid17">17</a>]), as is done with assisted conception techniques, because the patient population, treatment goals, and clinical outcome are distinctly different.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PCOS represents a risk factor for developing OHSS following ovarian stimulation with gonadotropins in any setting. (See  <a class="medical medical_review" href="/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome", section on 'Prevention of OHSS'</a>.)</p><p></p><p class="headingAnchor" id="H12667785"><span class="h2">Preconception counseling</span><span class="headingEndMark"> — </span>Like any couple planning fertility, couples considering ovulation induction should first undergo preconception counseling. Preconception care is a broad term that refers to the process of identifying social, behavioral, environmental, and biomedical risks to a woman's fertility and pregnancy outcome and then reducing these risks through education, counseling, and appropriate intervention. (See  <a class="medical medical_review" href="/d/html/448.html" rel="external">"The preconception office visit"</a>.)</p><p>In addition to a medical history and physical examination, the preconception assessment includes an assessment of rubella immunity and additional laboratory assessment based upon individual risk factors and local guidelines. (See  <a class="medical medical_review" href="/d/html/448.html" rel="external">"The preconception office visit", section on 'Laboratory assessment'</a> and  <a class="medical medical_review" href="/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.)</p><p>In addition, genetic carrier testing is performed based upon the woman or partner's medical history or family history of heritable disease. (See  <a class="medical medical_review" href="/d/html/463.html" rel="external">"Cystic fibrosis: Carrier screening"</a> and  <a class="medical medical_review" href="/d/html/428.html" rel="external">"Preconception and prenatal carrier screening for genetic disorders more common in people of Ashkenazi Jewish descent and others with a family history of these disorders"</a>.)</p><p>Serum anti-müllerian hormone (AMH) concentrations appear to be an early, reliable indicator of declining ovarian function. AMH is expressed by the small (&lt;8 mm) preantral and early antral follicles, and serum concentrations reflect the size of the primordial follicle pool and may be the best biochemical marker of ovarian function across an array of clinical situations. AMH has been used as a predictor of ovarian response to stimulation for in vitro fertilization (IVF) success; low levels correlate with reduced ovarian reserve, while high levels correlate with a vigorous response to ovarian stimulation and a higher risk of OHSS (see  <a class="medical medical_review" href="/d/html/5445.html" rel="external">"Female infertility: Evaluation", section on 'Anti-müllerian hormone'</a>). AMH may also be a predictor of ovulation induction success, but it has not been well validated in this setting.</p><p class="headingAnchor" id="H695051919"><span class="h2">Patient-specific approach</span><span class="headingEndMark"> — </span>The approach to ovulation induction depends upon the patient population; the different approaches are reviewed here briefly and in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional hypothalamic amenorrhea (FHA)</strong> –<strong> </strong>Women with FHA are hypoestrogenemic and are therefore unlikely to respond to <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, an antiestrogen. However, because clomiphene citrate is easy to administer, it may seem reasonable to give one course of clomiphene prior to initiating pulsatile gonadotropin-releasing hormone (GnRH) or gonadotropin therapy. For those who ovulate, clomiphene citrate can then be continued. For those who do not ovulate, we suggest pulsatile GnRH as first-line therapy in countries where it is available. If pulsatile GnRH is unavailable, gonadotropin therapy should be initiated, with both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (these women do not respond to FSH alone). (See <a class="local">'Pulsatile GnRH therapy'</a> below and <a class="local">'Gonadotropin therapy'</a> below and  <a class="medical medical_review" href="/d/html/7465.html" rel="external">"Isolated gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)", section on 'Ovulation induction in women'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polycystic ovary syndrome (PCOS)</strong> –<strong> </strong>The approach to women with PCOS starts with exercise and weight loss, if indicated, followed by ovulation induction. Weight loss should always be attempted in overweight or obese women with PCOS because ovulation can be restored with a modest amount of weight loss. For women with obesity and infertility who are &gt;40 years of age, clinicians need to balance the health benefits of weight loss against the loss of fertility potential that might occur due to a delay in initiation of ovulation induction. Fertility potential declines rapidly after 40 years of age. (See  <a class="medical medical_review" href="/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Weight loss'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">Letrozole</a> therapy, which results in higher live birth rates than <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate in women with PCOS (especially those with obesity), is now considered first-line therapy. However, ovulation induction is an off-label use of letrozole, so some women prefer to use clomiphene citrate and, in some countries, letrozole is not available. (See <a class="local">'Letrozole'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary ovarian insufficiency (POI)</strong> – All ovulation induction strategies for women with POI are unsuccessful, and we suggest against their use. Women with POI should be offered the option of IVF with donor oocytes as a successful way to fulfill their wish to have children. (See  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)"</a> and  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The treatment of choice for anovulatory women with hyperprolactinemia is dopamine agonists; this is reviewed in detail separately. (See <a class="local">'Dopamine agonists'</a> below and  <a class="medical medical_review" href="/d/html/6629.html" rel="external">"Management of lactotroph adenoma (prolactinoma) before and during pregnancy", section on 'Restoration of ovulation'</a>.)</p><p></p><p class="headingAnchor" id="H523298549"><span class="h1">ORAL AGENTS</span></p><p class="headingAnchor" id="H1250687695"><span class="h2">Letrozole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">Letrozole</a>, an aromatase inhibitor, blocks the conversion of testosterone and androstenedione to estradiol and <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a>, respectively (unlike <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>, which blocks estrogen action), thereby reducing negative estrogenic feedback at the pituitary and thus increasing follicle-stimulating hormone (FSH) output  (<a class="graphic graphic_figure graphicRef81745" href="/d/graphic/81745.html" rel="external">figure 2</a>). In contrast to clomiphene citrate, letrozole appears to be free of the adverse effects on endometrial and cervical mucus attributed to clomiphene citrate [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.)</p><p>For oligo-ovulatory women with polycystic ovary syndrome (PCOS) undergoing ovulation induction, we now suggest <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> as first-line therapy over <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, regardless of the patient's body mass index (BMI). Before starting letrozole, the clinician <strong>must</strong> discuss that this use of the drug is not US Food and Drug Administration (FDA) approved and that there is an available alternative (clomiphene citrate). This recommendation is consistent with current American College of Obstetrics and Gynecology (ACOG) guidelines for choice of ovulation induction agents in women with PCOS [<a href="#rid19">19</a>]. </p><p>A randomized trial [<a href="#rid20">20</a>] and a meta-analysis of 20 trials in nearly 4000 anovulatory women with PCOS [<a href="#rid21">21</a>] have both reported that <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> results in higher live birth rates compared with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> therapy. In contrast, clomiphene citrate is approved for ovulation induction and has been widely used for over 50 years [<a href="#rid22">22</a>]. Efficacy and safety of letrozole is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Clomiphene citrate</span><span class="headingEndMark"> — </span>In 1958, the nonsteroidal antiestrogen MER-25 was found to induce menstruation in an amenorrheic woman receiving the drug as an experimental treatment for endometrial cancer [<a href="#rid23">23</a>]. The next year, 43 anovulatory women given another antiestrogen, <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, also ovulated. Clomiphene, like <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">raloxifene</a>, belongs to the category of compounds known as selective estrogen receptor modulators (SERMs). These drugs are competitive inhibitors of estrogen binding to estrogen receptors and have mixed agonist and antagonist activity, depending upon the target tissue. While they could be used for ovulation induction, tamoxifen and raloxifene are less effective than clomiphene, so are not typically used for this purpose.</p><p><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> citrate has been the most widely used agent for ovulation induction for over 50 years. Most, but not all, women with PCOS ovulate in response to clomiphene citrate. However, clomiphene is no longer considered to be first-line therapy for women with PCOS. (See <a class="local">'Letrozole'</a> above and  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.)</p><p>Sixty to 85 percent of anovulatory women, typically with PCOS, ovulate in response to <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate. Of those who ovulate, approximately 50 percent do so at a dose of 50 mg daily for five days, often cycle days 3 to 7. Twin and triplet gestations occur in approximately 7 to 9 and 0.3 percent, respectively, of clomiphene-induced pregnancies. The incidence of miscarriage and birth defects appears to be similar to that in spontaneous pregnancies, and the rate of ectopic pregnancy is probably not increased. The risk of ovarian hyperstimulation syndrome (OHSS) is less than 1 percent. (See  <a class="medical medical_review" href="/d/html/7400.html" rel="external">"Ovulation induction with clomiphene citrate", section on 'Outcomes'</a>.)</p><p>Predictors of ovulation in one study included a lower free androgen index (FAI), a calculation of testosterone not bound to sex hormone-binding globulin (SHBG), lower body mass index (BMI), presence of oligomenorrhea (as opposed to amenorrhea), and lower ovarian volume [<a href="#rid24">24</a>]. Of those who ovulate, 30 to 40 percent conceive. In the study noted [<a href="#rid24">24</a>], predictors of pregnancy with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> included younger age, low BMI, low FAI, and oligomenorrhea rather than amenorrhea. A nomogram has been developed to help predict chances for live birth based upon simple, initial screening characteristics  (<a class="graphic graphic_figure graphicRef81180" href="/d/graphic/81180.html" rel="external">figure 3</a>). There is general agreement that women with obesity respond less favorably to clomiphene citrate ovulation induction.</p><p>Ovulation induction with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> is reviewed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7400.html" rel="external">"Ovulation induction with clomiphene citrate"</a> and  <a class="medical medical_review" href="/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Ovulation induction medications'</a>.)</p><p class="headingAnchor" id="H2828694759"><span class="h2">Metformin</span><span class="headingEndMark"> — </span>Correction of hyperinsulinemia with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> has been shown to have a beneficial effect in anovulatory women with PCOS by increasing menstrual cyclicity and improving spontaneous ovulation. However, it does <strong>not</strong> appear to improve live-birth rates when given alone or in combination with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate. This topic is discussed separately. There is some experience with the use of another insulin-sensitizing drug, (myo)inositol. Results of well-designed studies of sufficient sample size should be awaited. (See  <a class="medical medical_review" href="/d/html/7411.html" rel="external">"Metformin for treatment of the polycystic ovary syndrome", section on 'Anovulatory infertility'</a>.)</p><p class="headingAnchor" id="H523300123"><span class="h2">Dopamine agonists</span><span class="headingEndMark"> — </span>A dopamine agonist is the treatment of choice for women with hyperprolactinemic anovulation who are pursuing pregnancy. In women with a lactotroph adenoma, as an example, a marked reduction in the serum prolactin concentration occurs within two to three weeks  (<a class="graphic graphic_figure graphicRef72539" href="/d/graphic/72539.html" rel="external">figure 4</a>). (See  <a class="medical medical_review" href="/d/html/6629.html" rel="external">"Management of lactotroph adenoma (prolactinoma) before and during pregnancy", section on 'Dopamine agonist therapy'</a>.)</p><p><a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">Bromocriptine</a> is still sometimes used to restore ovulation in women with hyperprolactinemia. However, drugs that bind more specifically to dopamine D2 receptors on the lactotroph cells, such as <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>, are associated with fewer side effects. The fetal safety of bromocriptine is better established than cabergoline, but cabergoline appears to be safe as well. We typically let women choose which dopamine agonist they would like to try. Women who are especially concerned about the possibility of birth defects often choose bromocriptine, and women who are more concerned about nausea from bromocriptine typically choose cabergoline. (See  <a class="medical medical_review" href="/d/html/6629.html" rel="external">"Management of lactotroph adenoma (prolactinoma) before and during pregnancy", section on 'Choice of dopamine agonist'</a>.)</p><p>Dopamine agonist regimens and monitoring for ovulation induction are reviewed in detail separately. Treatment should be stopped once pregnancy has been diagnosed because the safety of continued usage has not been well established. During pregnancy, if a macroadenoma increases in size enough to cause visual field impairment, dopamine agonist therapy can be resumed. However, this is uncommon, as women with macroadenomas are counseled to avoid pregnancy until dopamine agonists are given to decrease its size  (<a class="graphic graphic_table graphicRef68772" href="/d/graphic/68772.html" rel="external">table 4</a>) [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/6629.html" rel="external">"Management of lactotroph adenoma (prolactinoma) before and during pregnancy", section on 'Patient counseling before pregnancy'</a>.)</p><p class="headingAnchor" id="H523299918"><span class="h1">PULSATILE GnRH THERAPY</span><span class="headingEndMark"> — </span>The pulsatile administration of gonadotropin-releasing hormone (GnRH) using an infusion pump stimulates the production of endogenous follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The resulting serum FSH and LH concentrations remain within the normal range, so the chances of multifollicular development and ovarian hyperstimulation are low. In comparison, continuous GnRH therapy lowers gonadotropin release  (<a class="graphic graphic_figure graphicRef51212" href="/d/graphic/51212.html" rel="external">figure 5</a>).</p><p class="headingAnchor" id="H523299966"><span class="h2">Indication</span><span class="headingEndMark"> — </span>Pulsatile GnRH administration is indicated for women with hypogonadotropic hypogonadism (hypothalamic amenorrhea [HA]) who have normal pituitary function. Because pulsatile GnRH therapy maintains normal feedback mechanisms, most cycles result in a single dominant follicle. Therefore, rates of multiple gestation are extremely low, and the risk of ovarian hyperstimulation syndrome (OHSS) in women with HA is exceedingly low [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/7465.html" rel="external">"Isolated gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)", section on 'Ovulation induction in women'</a>.)</p><p>Pulsatile GnRH has also been used with some success for women with polycystic ovary syndrome (PCOS). This approach is counterintuitive as women with PCOS typically have an increased hypothalamic GnRH pulse frequency and high serum LH concentrations. (See  <a class="medical medical_review" href="/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Ovulation induction medications'</a>.)</p><p class="headingAnchor" id="H695053072"><span class="h2">Protocol</span><span class="headingEndMark"> — </span>The intravenous (IV) route appears superior to the subcutaneous route. In order to mimic the normal pulsatile release of GnRH, the pulse interval is 60 to 90 minutes. The most physiologic dose for IV administration is 75 ng/kg [<a href="#rid26">26</a>] (in practice, some clinicians use 2.5 micrograms/pulse for women weighing &lt;50 kg and 5 micrograms/pulse for women weighing &gt;50 kg; others use doses ranging from 2.5 to 10 mcg per pulse, starting with 2.5 mcg and increasing until the minimum dose to induce ovulation is reached). In published studies, pulsatile GnRH is continued for the entire cycle. In the clinical setting, pulsatile GnRH administration may be discontinued after ovulation and the corpus luteum supported by human chorionic gonadotropin (hCG). A potential regimen for luteal phase hCG administration that has been used with gonadotropin therapy is 500 units administered on days 7, 10, and 13 after ovulation.</p><p>Women being treated with IV pulsatile GnRH should be seen weekly to monitor the IV site for swelling, pain, or erythema. We monitor the patient's initial cycles with ultrasound until we are confident that a dose that will induce ovulation has been reached. Serum estradiol monitoring is not necessary. Once ultrasound monitoring is stopped, the patient can predict ovulation in subsequent cycles with urinary LH kits. We confirm ovulation in subsequent cycles by measuring a luteal phase progesterone concentration.</p><p class="headingAnchor" id="H523300024"><span class="h2">Results</span><span class="headingEndMark"> — </span>Ovulation rates of 90 percent and pregnancy rates of 80 percent or higher have been reported in women treated with pulsatile GnRH [<a href="#rid15">15,27</a>]. Local complications such as phlebitis may occasionally occur.</p><p>Pulsatile GnRH is currently unavailable in the United States but is widely used in other parts of the world. A smaller infusion device has been introduced.</p><p class="headingAnchor" id="H14"><span class="h1">GONADOTROPIN THERAPY</span><span class="headingEndMark"> — </span>Since their introduction into clinical practice in 1961, gonadotropins extracted from the urine of postmenopausal women (<a class="drug drug_general" data-topicid="9607" href="/d/drug information/9607.html" rel="external">human menopausal gonadotropins</a> [hMG]), in which the ratio of luteinizing hormone (LH) to follicle-stimulating hormone (FSH) bioactivity is 1:1, have assumed a central role in ovulation induction [<a href="#rid28">28</a>]. Refinement of the initially crude preparation resulted in the availability of purified and highly purified urinary FSH (uFSH). Since 1996, recombinant human FSH (rhFSH, &gt;99 percent purity) has been available. Recombinant preparations are appealing due to their ease of administration (subcutaneous rather than intramuscular), purity, and batch-to-batch consistency.</p><p class="headingAnchor" id="H15"><span class="h2">Candidates</span><span class="headingEndMark"> — </span>There are several indications for gonadotropin therapy in anovulatory women:</p><p class="bulletIndent1"><span class="glyph">●</span>Women with polycystic ovary syndrome (PCOS) who have not ovulated or conceived with weight loss, <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>, or <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> therapy  (<a class="graphic graphic_table graphicRef56718" href="/d/graphic/56718.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypogonadotropic anovulatory women with hypopituitarism or women with hypothalamic amenorrhea (HA) who do not have access to pulsatile gonadotropin-releasing hormone (GnRH) therapy. (See <a class="local">'Pulsatile GnRH therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H523302116"><span class="h2">Preparations</span></p><p class="headingAnchor" id="H695052741"><span class="h3">hMG and FSH</span><span class="headingEndMark"> — </span>The degree to which the type of follicle-stimulating hormone (FSH) compound employed may influence outcome of ovulation induction has been controversial. However, in a meta-analysis of 14 trials in 1726 women (10 trials comparing rhFSH and urinary gonadotropins [FSH-highly purified (HP) or <a class="drug drug_general" data-topicid="9607" href="/d/drug information/9607.html" rel="external">human menopausal gonadotropins</a> (hMG)] and four trials comparing FSH-purified [P] and hMG or HP-hMG), the following results were seen [<a href="#rid29">29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>There were no differences in clinical pregnancy or live-birth rates for rhFSH and urinary-derived gonadotropins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There also were no differences between hMG preparations and urinary FSH-P.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After pooling the data, there were no differences in the rates of ovarian hyperstimulation syndrome (OHSS) between rhFSH and urinary-derived gonadotropins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evidence for all outcomes was of very low quality.</p><p></p><p>Purified uFSH has some LH activity, but rhFSH does not. The experience with rhFSH in hypogonadotropic hypogonadal women indicates that those women who have very low serum LH concentrations (&lt;0.5 international units/L) need exogenous human chorionic gonadotropin (hCG) (or 75 international units/day subcutaneous recombinant LH) to maintain adequate estradiol biosynthesis and follicle development [<a href="#rid30">30</a>].</p><p>Long-acting rhFSH preparations are currently registered in some countries for use in in vitro fertilization (IVF) [<a href="#rid31">31</a>], but their use is not advised for ovulation induction.</p><p class="headingAnchor" id="H695052747"><span class="h3">Ovulatory triggers</span><span class="headingEndMark"> — </span>hCG is used to trigger ovulation when the ovarian follicles are mature. Both urinary and recombinant hCG preparations are available. A dose of 250 mcg of recombinant hCG appears to be equivalent to the standard doses of urinary hCG (5000 to 10,000 units) [<a href="#rid32">32</a>].</p><p>Other ovulatory triggers, such as recombinant LH, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p class="headingAnchor" id="H523298629"><span class="h2">Protocols</span><span class="headingEndMark"> — </span>The aim of ovulation induction with gonadotropins, as with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>, is the formation of a single dominant follicle. In spontaneous cycles, this is achieved at the beginning of the cycle by a transient increase in serum FSH concentrations above the threshold value  (<a class="graphic graphic_figure graphicRef61116" href="/d/graphic/61116.html" rel="external">figure 1</a>) [<a href="#rid33">33</a>]. The concentrations then decrease due to negative feedback, preventing more than one follicle from undergoing preovulatory development  (<a class="graphic graphic_figure graphicRef60133" href="/d/graphic/60133.html" rel="external">figure 6</a>). Because ovarian sensitivity to FSH stimulation varies among individual women, specific treatment and monitoring protocols are needed to achieve development of a single follicle when exogenous gonadotropin is administered.</p><p>In the <strong>conventional gonadotropin protocol</strong>, the starting dose of FSH is 150 international units/day. However, this regimen is associated with a multiple pregnancy rate of up to 36 percent, and ovarian hyperstimulation occurs in up to 14 percent of treatment cycles [<a href="#rid33">33</a>].</p><p>In patients with PCOS, who are at particular risk for complications, this approach has been largely abandoned in favor of a <strong>low-dose, step-up protocol</strong> [<a href="#rid34">34</a>] designed to allow the FSH threshold to be reached gradually, minimizing excessive stimulation and therefore the risk of development of multiple follicles. In this protocol, the initial subcutaneous or intramuscular dose of FSH is 37.5 to 75 international units/day. It is recommended that the dose be increased only if, after 14 days, no response is documented on ultrasonography and serum estradiol monitoring. Increments of 37.5 international units then are given at weekly intervals up to a maximum of 225 international units/day  (<a class="graphic graphic_figure graphicRef58611" href="/d/graphic/58611.html" rel="external">figure 7</a>). The optimal interval for increasing the dose has not been well studied in PCOS patients.</p><p>The detection of an ovarian response is an indication to continue the current dose [<a href="#rid35">35-37</a>] until hCG can be given to trigger ovulation, as described below. (See <a class="local">'Preparations'</a> above.)</p><p>The <strong>low-dose, step-down protocol</strong> of ovulation induction mimics more closely the physiology of normal cycles [<a href="#rid38">38</a>]. Therapy with 150 international units FSH/day is started shortly after spontaneous or progesterone-induced bleeding and continued until a dominant follicle (&gt;10 mm) is seen on transvaginal ultrasonography. The dose is then decreased to 112.5 international units/day followed by a further decrease to 75 international units/day three days later, which is continued until hCG is administered to induce ovulation. The appropriate starting dose can be determined by using the low-dose, step-up regimen for the first treatment cycle [<a href="#rid39">39</a>]. The robustness of the step-down regimen in everyday practice remains to be evaluated, and hence, the low-dose, step-up regimen should be considered the first choice treatment.</p><p class="headingAnchor" id="H20"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>The ovarian response to gonadotropin therapy is monitored using <strong>transvaginal ultrasonography </strong>to measure follicular diameter. The scans during the late follicular phase, usually performed every two or three days, should be focused on identifying follicles of intermediate size.</p><p>hCG is given as an ovulatory trigger on the day that at least one follicle appears to be mature. The criteria for follicle maturity are a follicle diameter of 18 mm and/or a serum estradiol concentration of 200 pg/mL (734 pmol/L) per dominant follicle. Available hCG preparations are reviewed in the preceding section. (See <a class="local">'Preparations'</a> above.)</p><p>If three or more follicles larger than 15 mm are present, stimulation should be stopped, hCG withheld, and use of a barrier contraceptive advised in order to prevent multiple pregnancies and ovarian hyperstimulation. Measurements of serum estradiol are useful; preovulatory concentrations above the normal range may predict ovarian hyperstimulation. (See  <a class="medical medical_review" href="/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome"</a> and  <a class="medical medical_review" href="/d/html/7417.html" rel="external">"Strategies to control the rate of high order multiple gestation"</a> and  <a class="medical medical_review" href="/d/html/4998.html" rel="external">"Neonatal complications of multiple births"</a>.)</p><p>Serum progesterone measurements are sometimes useful before administration of hCG to determine if a premature LH surge has occurred, although we do not suggest routine progesterone measurements.</p><p class="headingAnchor" id="H21"><span class="h2">Outcomes</span></p><p class="headingAnchor" id="H695050344"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>A series of 225 women with PCOS treated over a 10-year period in one center found rates of ovulation and pregnancy of 72 percent and 45 percent, respectively, after use of the low-dose, step-up protocol [<a href="#rid34">34</a>]. Multiple folliculogenesis and ovarian hyperstimulation are less common than that seen with the standard protocol, and pregnancy rates appear similar [<a href="#rid40">40-42</a>]. However, the results of the low-dose, step-up protocol are negatively influenced by age and obesity.</p><p>Gonadotropin therapy after <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> treatment has failed has been the "classical" approach to ovulation induction for anovulatory infertility. Using this sequential approach, cumulative, singleton live-birth rates of 71 percent (only 7 percent multiples) over 24 months have been reported  (<a class="graphic graphic_figure graphicRef66367" href="/d/graphic/66367.html" rel="external">figure 8</a>) [<a href="#rid14">14</a>]. These results suggest that conventional approaches offer an effective means of treating the majority of women with anovulatory infertility before proceeding to more aggressive treatments such as IVF.</p><p>Ovulation induction is sometimes combined with intrauterine insemination (IUI). In the absence of male factor infertility, this clinical approach is not based on sound clinical evidence. If both anovulatory and male factor infertility are causing the couple's infertility, then combined ovulation induction with IUI is a useful approach.</p><p>Obesity and insulin resistance (but not an elevated serum LH concentration) are associated with lower success rates [<a href="#rid14">14,43,44</a>].</p><p class="headingAnchor" id="H22"><span class="h3">Multiple gestation</span><span class="headingEndMark"> — </span>The risk of multiple gestation is increased with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate but to a much greater extent with gonadotropin therapy. The reasons for multiple gestation and strategies to lower risk are described in detail elsewhere [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/4998.html" rel="external">"Neonatal complications of multiple births"</a> and  <a class="medical medical_review" href="/d/html/7417.html" rel="external">"Strategies to control the rate of high order multiple gestation", section on 'Limiting the multiple gestation risk of ovulation induction and superovulation'</a>.)</p><p class="headingAnchor" id="H523302280"><span class="h3">Ovarian hyperstimulation syndrome</span><span class="headingEndMark"> — </span>OHSS is a potentially life-threatening complication of ovulation induction. Its most severe manifestations include massive ovarian enlargement and multiple cysts, hemoconcentration, and third-space accumulation of fluid; these changes may be complicated by renal failure, hypovolemic shock, thromboembolic episodes, acute respiratory distress syndrome, and death [<a href="#rid46">46-51</a>]. This topic is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"</a> and  <a class="medical medical_review" href="/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome"</a> and  <a class="medical medical_review" href="/d/html/101383.html" rel="external">"Management of ovarian hyperstimulation syndrome"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Adjuvant treatment</span><span class="headingEndMark"> — </span>Adjuvant GnRH agonists or antagonists are commonly used for women with ovulatory infertility undergoing "ovarian hyperstimulation" with gonadotropins in the setting of IVF. The goal is to suppress pituitary gonadotropins to optimize control of the cycle and prevent a premature rise of endogenous LH prior to full maturation of the cohort of ovarian follicles. (See  <a class="medical medical_review" href="/d/html/134342.html" rel="external">"In vitro fertilization: Procedure", section on 'Ovarian stimulation'</a>.)</p><p>Similar strategies have been proposed to improve outcomes in anovulatory women undergoing ovulation induction with gonadotropins. However, insufficient data are available to conclude whether GnRH agonists may improve pregnancy or OHSS rates [<a href="#rid52">52</a>]. Similarly, there are insufficient data to draw conclusions regarding the possible role of GnRH antagonists as adjuvant therapy.</p><p class="headingAnchor" id="H523301066"><span class="h1">LAPAROSCOPIC OVARIAN DIATHERMY</span><span class="headingEndMark"> — </span>Laparoscopic ovarian diathermy ("ovarian drilling") represents an alternative second-line therapy for women with polycystic ovarian syndrome (PCOS). In women who are still anovulatory despite an adequate trial of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, another therapeutic option next to gonadotropins is laparoscopic surgery with electrocautery or laser. This topic is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Laparoscopic surgery'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">CANCER RISKS</span><span class="headingEndMark"> — </span>Ovulation-induction drugs are used in virtually all fertility treatment regimens. All result in a temporary increase in serum concentrations of estrogen and progesterone. There have been concerns that this could affect the risk of hormone-sensitive cancers, but available data suggest that this is not the case. [<a href="#rid53">53,54</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovarian cancer </strong>–<strong> </strong>In some early studies, it appeared that the use of fertility drugs was associated with neoplasia, particularly borderline ovarian tumors [<a href="#rid55">55-57</a>]. Subsequent studies and meta-analyses have not confirmed an excess risk of ovarian cancer with infertility treatment (<a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> or gonadotropin therapy), but in some reports, infertility itself was an independent risk factor [<a href="#rid57">57-65</a>] (see  <a class="medical medical_review" href="/d/html/6788.html" rel="external">"Assisted reproductive technology: Pregnancy and maternal outcomes", section on 'Ovarian cancer and borderline tumors'</a>). Thus, the initial observation that fertility drug use was linked to epithelial ovarian cancer appears to be explained by the fact that these drugs are more likely to be used in infertile women [<a href="#rid56">56,66</a>]. This hypothesis is supported by the observation that nulliparous women with refractory infertility may harbor a particularly high risk of epithelial ovarian cancer, irrespective of their use of fertility drugs [<a href="#rid64">64,66-69</a>].</p><p></p><p class="bulletIndent1">The best evidence for a lack of association comes from a systematic review of 11 case-control studies and 14 cohort studies that included a total of 182,972 women. In this analysis, there was no convincing evidence of an excess risk of invasive ovarian tumors with fertility drug therapy [<a href="#rid65">65</a>]. However, there was a possible excess risk of borderline ovarian tumors in subfertile women undergoing in vitro fertilization (IVF), but there were methodological limitations, including a high risk of bias and small number of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer </strong>–<strong> </strong>There does <strong>not</strong> appear to be an increased risk of breast cancer in women treated with fertility drugs [<a href="#rid59">59,60,70-74</a>]. However, interpretation of the available data is limited by several factors, such as survey information, small subgroup numbers, lack of evaluation by drug type/dose or cause of infertility, and confounding by the presence of other risk factors for breast cancer. (See  <a class="medical medical_review" href="/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women"</a>.)</p><p></p><p class="bulletIndent1">One relatively large, case-control study showed that infertile women with breast cancer were more likely to have been treated with human menopausal gonadotropin (hMG) for more than six cycles than infertile women without breast cancer; no increased risk was noted for <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate [<a href="#rid75">75</a>]. However, this study was subject to many of the limitations noted above.</p><p></p><p class="bulletIndent1">In contrast, in a prospective cohort study of 116,671 women with 1357 incident cases of breast cancer, women who reported infertility due to an ovulatory disorder had a lower risk of breast cancer than women who did not report infertility (hazard ratio [HR] 0.75) [<a href="#rid76">76</a>]; women who had received <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate were at lowest risk (HR 0.60). In a sister-matched, case-control study among approximately 1400 women with and 1600 sisters without breast cancer, those who had used clomiphene citrate or exogenous follicle-stimulating hormone (FSH) but did not conceive were at lower risk of breast cancer compared with nonusers (odds ratio [OR] 0.62, 95% CI 0.43-0.89). Those who used fertility drugs and did conceive (at least a 10-week pregnancy) had the same breast cancer risk as women who had never taken fertility drugs [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1">Thus, women taking infertility drugs can be reassured that these drugs probably do not increase their risk of breast cancer, although it is not clear whether some subgroups may be at increased risk. Further investigation is required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other ovulation induction drugs </strong>– Other ovulation induction therapies discussed below (including pulsatile gonadotropin-releasing hormone [GnRH] and dopamine agonists) have not been linked to ovarian or breast cancer risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colorectal cancer – </strong>Sex hormones may play a role in the etiology of colon cancer. Rates are higher in men compared with women, and exogenous estrogens (oral contraceptives and menopausal hormone therapy) have been associated with a slightly lower risk of colon cancer in some studies [<a href="#rid78">78-80</a>]. The impact of ovulation induction agents, which increase circulating estrogen levels, has not been well studied. However, in a population-based cohort study of nearly 150,000 women, no change in colon cancer risk was observed with the use of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, exogenous gonadotropins, human chorionic gonadotropin (hCG), or GnRH agonists [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/d/html/2606.html" rel="external">"Epidemiology and risk factors for colorectal cancer", section on 'Hormone therapy in females'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other cancers</strong> –<strong> </strong>In a retrospective, cohort study, neither <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> nor gonadotropin use appeared to be associated with an increased risk of melanoma, thyroid, or cervical cancers [<a href="#rid82">82</a>]. In contrast, the same investigators reported that clomiphene use may be associated with a greater risk of endometrial cancer. However, one explanation for these findings is that infertile women who used clomiphene were more likely to have underlying chronic anovulation, which is a strong risk factor for development of endometrial cancer. (See  <a class="medical medical_review" href="/d/html/7400.html" rel="external">"Ovulation induction with clomiphene citrate", section on 'Cancer risks'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk in offspring </strong>– A large, population-based study found that childhood tumor risk was not increased in children conceived following ovulation induction [<a href="#rid83">83</a>]. Ongoing monitoring of the long-term effects of these drugs is warranted since the number of cases was small. However, congenital malformation risk does not appear to be increased with oral ovulation induction agents (see  <a class="medical medical_review" href="/d/html/7400.html" rel="external">"Ovulation induction with clomiphene citrate"</a>). Pregnancy outcome after assisted reproductive technologies (ART) is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6788.html" rel="external">"Assisted reproductive technology: Pregnancy and maternal outcomes"</a>.)</p><p></p><p class="headingAnchor" id="H2277984414"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110097.html" rel="external">"Society guideline links: Polycystic ovary syndrome"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114191.html" rel="external">"Society guideline links: Female infertility"</a>.)</p><p class="headingAnchor" id="H40"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/8418.html" rel="external">"Patient education: Infertility treatment with gonadotropins (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H41"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> –<strong> </strong>Ovulatory disorders are a common cause of infertility, which in most cases is treatable with ovulation induction agents. The goal of therapy in these women is monofollicular development and subsequent ovulation. This approach should be differentiated from stimulation of multiple follicle development in ovulatory women, as is done with assisted reproductive technologies (ART). (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1">The method of ovulation induction selected by the clinician should be based upon the underlying cause of anovulation and the efficacy, costs, risks, burden of treatment, and potential complications associated with each method as they apply to the individual woman. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypogonadotropic hypogonadism</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulsatile GnRH</strong> –<strong> </strong>For women with hypogonadotropic amenorrhea, we suggest pulsatile gonadotropin-releasing hormone (GnRH) as first-line therapy in women with intact pituitary function in countries where it is available (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Because <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate is easy to administer, it is reasonable to give one course of clomiphene prior to initiating pulsatile GnRH. However, very few women in this group respond. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gonadotropin therapy</strong> –<strong> </strong>If pulsatile GnRH is unavailable, gonadotropin therapy should be initiated, with <strong>both</strong> luteinizing hormone (LH) and follicle-stimulating hormone (FSH; these women do not respond to FSH alone). The low-dose, step-up regimen is considered to be the first-choice treatment. (See <a class="local">'Patient-specific approach'</a> above and <a class="local">'Protocols'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polycystic ovary syndrome (PCOS)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Letrozole</strong><strong> and </strong><strong>clomiphene</strong> –<strong> </strong>For oligo-ovulatory women with PCOS undergoing ovulation induction, we suggest <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> as first-line therapy over <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, regardless of the patient's body mass index (BMI) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Before starting letrozole, the clinician <strong>must</strong> discuss that this use of the drug is not approved for ovulation induction. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole", section on 'Suggested approach'</a>.)</p><p></p><p class="bulletIndent2">Doses, regimens, and monitoring for <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> and <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> use in women with PCOS are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7400.html" rel="external">"Ovulation induction with clomiphene citrate"</a> and  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lifestyle changes</strong> –<strong> </strong>For women with obesity and PCOS, we also implement lifestyle changes and weight loss as an initial strategy to restore ovulatory cycles. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole", section on 'Suggested approach'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gonadotropin therapy</strong> –<strong> </strong>If oral ovulation induction agents are unsuccessful in women with PCOS, then gonadotropin therapy should be started (in this case, FSH alone is sufficient). Strict attention to follicle number is essential to avoid multiple gestation and ovarian hyperstimulation. (See <a class="local">'Gonadotropin therapy'</a> above.)</p><p></p><p class="bulletIndent2">To minimize the risk of multiple gestation and ovarian hyperstimulation syndrome (OHSS) in PCOS, gonadotropin treatment should be stopped if there are an excess number of follicles or extremely high serum estradiol concentrations. (See <a class="local">'Monitoring'</a> above and  <a class="medical medical_review" href="/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome"</a> and  <a class="medical medical_review" href="/d/html/7417.html" rel="external">"Strategies to control the rate of high order multiple gestation", section on 'Limiting the multiple gestation risk of ovulation induction and superovulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary ovarian insufficiency</strong> –<strong> </strong>For women with primary ovarian insufficiency (POI; premature ovarian failure) no ovulation induction strategy has been shown to be effective. However, in vitro fertilization (IVF) with donor oocytes has high success rates. (See  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperprolactinemia</strong> –<strong> </strong>For women with hyperprolactinemic anovulation, we suggest ovulation induction with dopamine agonists (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Although we typically start with <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>, <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> is a reasonable choice as well. (See <a class="local">'Dopamine agonists'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer risks</strong> –<strong> </strong>While there has been concern about a possible increased risk of ovarian cancer with ovulation induction drugs, it appears that the risk may be due to the infertility itself rather than the medications used to treat it. However, because one study suggested an increase after 12 cycles of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, women should not receive more than 12 cycles. There does not appear to be an increased risk of breast cancer or colon cancer with ovulation induction drugs. (See <a class="local">'Cancer risks'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hull MG, Glazener CM, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 1985; 291:1693.</a></li><li><a class="nounderline abstract_t">Daan NM, Louwers YV, Koster MP, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril 2014; 102:1444.</a></li><li><a class="nounderline abstract_t">De Souza MJ, Miller BE, Loucks AB, et al. High frequency of luteal phase deficiency and anovulation in recreational women runners: blunted elevation in follicle-stimulating hormone observed during luteal-follicular transition. J Clin Endocrinol Metab 1998; 83:4220.</a></li><li><a class="nounderline abstract_t">Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 2002; 57:755.</a></li><li><a class="nounderline abstract_t">Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41.</a></li><li><a class="nounderline abstract_t">Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13:251.</a></li><li><a class="nounderline abstract_t">Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:673.</a></li><li><a class="nounderline abstract_t">de Wilde MA, Veltman-Verhulst SM, Goverde AJ, et al. Preconception predictors of gestational diabetes: a multicentre prospective cohort study on the predominant complication of pregnancy in polycystic ovary syndrome. Hum Reprod 2014; 29:1327.</a></li><li><a class="nounderline abstract_t">Christ JP, Gunning MN, Meun C, et al. Pre-Conception Characteristics Predict Obstetrical and Neonatal Outcomes in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2019; 104:809.</a></li><li><a class="nounderline abstract_t">Gunning MN, Sir Petermann T, Crisosto N, et al. Cardiometabolic health in offspring of women with PCOS compared to healthy controls: a systematic review and individual participant data meta-analysis. Hum Reprod Update 2020; 26:103.</a></li><li><a class="nounderline abstract_t">Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 2016; 22:687.</a></li><li><a class="nounderline abstract_t">De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010; 376:911.</a></li><li><a class="nounderline abstract_t">Kawamura K, Ishizuka B, Hsueh AJW. Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve. Reprod Biomed Online 2020; 40:245.</a></li><li><a class="nounderline abstract_t">Eijkemans MJ, Imani B, Mulders AG, et al. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 2003; 18:2357.</a></li><li><a class="nounderline abstract_t">Martin KA, Hall JE, Adams JM, Crowley WF Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1993; 77:125.</a></li><li><a class="nounderline abstract_t">Veltman-Verhulst SM, Fauser BC, Eijkemans MJ. High singleton live birth rate confirmed after ovulation induction in women with anovulatory polycystic ovary syndrome: validation of a prediction model for clinical practice. Fertil Steril 2012; 98:761.</a></li><li><a class="nounderline abstract_t">Zegers-Hochschild F, Adamson GD, Dyer S, et al. The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril 2017; 108:393.</a></li><li><a class="nounderline abstract_t">Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001; 75:305.</a></li><li><a class="nounderline abstract_t">ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice. Obstet Gynecol 2018; 131:1.</a></li><li><a class="nounderline abstract_t">Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014; 371:119.</a></li><li><a class="nounderline abstract_t">Wang R, Li W, Bordewijk EM, et al. First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum Reprod Update 2019; 25:717.</a></li><li><a class="nounderline abstract_t">Fauser BC. Reproductive endocrinology: revisiting ovulation induction in PCOS. Nat Rev Endocrinol 2014; 10:704.</a></li><li><a class="nounderline abstract_t">KISTNER RW, SMITH OW. Observations on the use of a non-steroidal estrogen antagonist: MER-25. Surg Forum 1960; 10:725.</a></li><li><a class="nounderline abstract_t">Imani B, Eijkemans MJ, te Velde ER, et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002; 77:91.</a></li><li><a class="nounderline abstract_t">Weil C. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 1986; 10:172.</a></li><li><a class="nounderline abstract_t">Martin K, Santoro N, Hall J, et al. Clinical review 15: Management of ovulatory disorders with pulsatile gonadotropin-releasing hormone. J Clin Endocrinol Metab 1990; 71:1081A.</a></li><li><a class="nounderline abstract_t">Filicori M, Flamigni C, Dellai P, et al. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 1994; 79:1215.</a></li><li><a class="nounderline abstract_t">Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update 2004; 10:453.</a></li><li><a class="nounderline abstract_t">Weiss NS, Nahuis M, Bayram N, et al. Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome. Cochrane Database Syst Rev 2015; :CD010290.</a></li><li><a class="nounderline abstract_t">European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001; 86:2607.</a></li><li><a class="nounderline abstract_t">Devroey P, Boostanfar R, Koper NP, et al. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009; 24:3063.</a></li><li><a class="nounderline abstract_t">Ludwig M, Doody KJ, Doody KM. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 2003; 79:1051.</a></li><li><a class="nounderline abstract_t">Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997; 18:71.</a></li><li><a class="nounderline abstract_t">White DM, Polson DW, Kiddy D, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996; 81:3821.</a></li><li><a class="nounderline abstract_t">Balen AH, Braat DD, West C, et al. Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. Hum Reprod 1994; 9:1563.</a></li><li><a class="nounderline abstract_t">Homburg R, Levy T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 1995; 63:729.</a></li><li><a class="nounderline abstract_t">Hedon B, Hugues JN, Emperaire JC, et al. A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hum Reprod 1998; 13:2688.</a></li><li><a class="nounderline abstract_t">van Santbrink EJ, Donderwinkel PF, van Dessel TJ, Fauser BC. Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod 1995; 10:1048.</a></li><li><a class="nounderline abstract_t">Imani B, Eijkemans MJ, Faessen GH, et al. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril 2002; 77:83.</a></li><li><a class="nounderline abstract_t">Buvat J, Buvat-Herbaut M, Marcolin G, et al. Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. Fertil Steril 1989; 52:553.</a></li><li><a class="nounderline abstract_t">Shoham Z, Patel A, Jacobs HS. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil Steril 1991; 55:1051.</a></li><li><a class="nounderline abstract_t">Calaf Alsina J, Ruiz Balda JA, Romeu Sarrió A, et al. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG 2003; 110:1072.</a></li><li><a class="nounderline abstract_t">Mulders AG, Eijkemans MJ, Imani B, Fauser BC. Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reprod Biomed Online 2003; 7:170.</a></li><li><a class="nounderline abstract_t">Mulders AG, Laven JS, Imani B, et al. IVF outcome in anovulatory infertility (WHO group 2)--including polycystic ovary syndrome--following previous unsuccessful ovulation induction. Reprod Biomed Online 2003; 7:50.</a></li><li><a class="nounderline abstract_t">Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005; 365:1807.</a></li><li><a class="nounderline abstract_t">Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002; 8:559.</a></li><li><a class="nounderline abstract_t">Delvigne A, Dubois M, Battheu B, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 1993; 8:1361.</a></li><li><a class="nounderline abstract_t">Navot D, Relou A, Birkenfeld A, et al. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988; 159:210.</a></li><li><a class="nounderline abstract_t">Delvigne A. Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS. Reprod Biomed Online 2009; 19:8.</a></li><li><a class="nounderline abstract_t">Enskog A, Henriksson M, Unander M, et al. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999; 71:808.</a></li><li><a class="nounderline abstract_t">Lewis CG, Warnes GM, Wang XJ, Matthews CD. Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normal cycling women. Fertil Steril 1990; 53:1097.</a></li><li><a class="nounderline abstract_t">Nugent D, Vandekerckhove P, Hughes E, et al. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2000; :CD000410.</a></li><li><a class="nounderline abstract_t">Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev 2019; 6:CD008215.</a></li><li><a class="nounderline abstract_t">Reigstad MM, Storeng R, Myklebust TÅ, et al. Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study. Cancer Epidemiol Biomarkers Prev 2017; 26:953.</a></li><li><a class="nounderline abstract_t">Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771.</a></li><li><a class="nounderline abstract_t">Shushan A, Paltiel O, Iscovich J, et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996; 65:13.</a></li><li><a class="nounderline abstract_t">Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217.</a></li><li><a class="nounderline abstract_t">Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996; 66:499.</a></li><li><a class="nounderline abstract_t">Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354:1586.</a></li><li><a class="nounderline abstract_t">Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147:1038.</a></li><li><a class="nounderline abstract_t">Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 2009; 169:365.</a></li><li><a class="nounderline abstract_t">Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 2004; 103:785.</a></li><li><a class="nounderline abstract_t">Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004; 103:1194.</a></li><li><a class="nounderline abstract_t">Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004; 82:405.</a></li><li><a class="nounderline abstract_t">Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev 2013; :CD008215.</a></li><li><a class="nounderline abstract_t">Rodriguez C, Tatham LM, Calle EE, et al. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control 1998; 9:645.</a></li><li class="breakAll">American College of Obstetricians and Gynecologists. Management of infertility caused by ovulatory dysfunction. ACOG practice bulletin #34. American College of Obstetricians and Gynecologists, Washington, DC 2002.</li><li><a class="nounderline abstract_t">Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1212.</a></li><li><a class="nounderline abstract_t">Rossing MA, Tang MT, Flagg EW, et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004; 160:1070.</a></li><li><a class="nounderline abstract_t">Ricci E, Parazzini F, Negri E, et al. Fertility drugs and the risk of breast cancer. Hum Reprod 1999; 14:1653.</a></li><li><a class="nounderline abstract_t">Rossing MA, Daling JR, Weiss NS, et al. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996; 60:3.</a></li><li><a class="nounderline abstract_t">Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002; 17:2209.</a></li><li><a class="nounderline abstract_t">Brinton LA, Scoccia B, Moghissi KS, et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod 2004; 19:2005.</a></li><li><a class="nounderline abstract_t">Gauthier E, Paoletti X, Clavel-Chapelon F, E3N group. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod 2004; 19:2216.</a></li><li><a class="nounderline abstract_t">Burkman RT, Tang MT, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril 2003; 79:844.</a></li><li><a class="nounderline abstract_t">Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med 2006; 166:2484.</a></li><li><a class="nounderline abstract_t">Fei C, Deroo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: results from the Two Sister Study. J Natl Cancer Inst 2012; 104:1021.</a></li><li><a class="nounderline abstract_t">Lope V, Fernández de Larrea N, Pérez-Gómez B, et al. Menstrual and Reproductive Factors and Risk of Gastric and Colorectal Cancer in Spain. PLoS One 2016; 11:e0164620.</a></li><li><a class="nounderline abstract_t">Luan NN, Wu L, Gong TT, et al. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies. Cancer Causes Control 2015; 26:65.</a></li><li><a class="nounderline abstract_t">Lin KJ, Cheung WY, Lai JY, Giovannucci EL. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 2012; 130:419.</a></li><li><a class="nounderline abstract_t">Møller M, Kjær SK, Lindquist S, et al. Risk of colorectal cancer after use of fertility drugs-results from a large Danish population-based cohort of women with infertility. Fertil Steril 2022; 118:738.</a></li><li><a class="nounderline abstract_t">Althuis MD, Scoccia B, Lamb EJ, et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005; 193:668.</a></li><li><a class="nounderline abstract_t">Brinton LA, Krüger Kjaer S, Thomsen BL, et al. Childhood tumor risk after treatment with ovulation-stimulating drugs. Fertil Steril 2004; 81:1083.</a></li></ol></div><div id="topicVersionRevision">Topic 7407 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3935248" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Population study of causes, treatment, and outcome of infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25239303" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9851755" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : High frequency of luteal phase deficiency and anovulation in recreational women runners: blunted elevation in follicle-stimulating hormone observed during luteal-follicular transition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12447098" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : New approach to polycystic ovary syndrome and other forms of anovulatory infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14688154" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12128286" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The role of lifestyle modification in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16891296" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777850" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Preconception predictors of gestational diabetes: a multicentre prospective cohort study on the predominant complication of pregnancy in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30590587" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pre-Conception Characteristics Predict Obstetrical and Neonatal Outcomes in Women With Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31867675" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cardiometabolic health in offspring of women with PCOS compared to healthy controls: a systematic review and individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27511809" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20708256" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary ovarian insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31753712" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14585887" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8325934" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633255" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High singleton live birth rate confirmed after ovulation induction in women with anovulatory polycystic ovary syndrome: validation of a prediction model for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28760517" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The International Glossary on Infertility and Fertility Care, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172831" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794680" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006718" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31647106" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178733" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Reproductive endocrinology: revisiting ovulation induction in PCOS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14409473" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Observations on the use of a non-steroidal estrogen antagonist: MER-25.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779596" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3525009" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2229271" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical review 15: Management of ovulatory disorders with pulsatile gonadotropin-releasing hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962297" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388674" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Historical perspectives in gonadotrophin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26350625" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11397861" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19684043" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738494" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of recombinant human chorionic gonadotropin in ovulation induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9034787" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Manipulation of human ovarian function: physiological concepts and clinical consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8923819" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7989523" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7890055" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9804214" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657739" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779595" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2509248" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1903725" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14664878" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14567885" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930574" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : IVF outcome in anovulatory infertility (WHO group 2)--including polycystic ovary syndrome--following previous unsuccessful ovulation induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15910954" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Multiple birth resulting from ovarian stimulation for subfertility treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12498425" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8253918" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3134814" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk factors and prognostic variables in the ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19573285" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10231037" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2112494" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normal cycling women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11034687" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31207666" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28108444" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8065405" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ovarian tumors in a cohort of infertile women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557128" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Human menopausal gonadotropin and the risk of epithelial ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821246" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8816606" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Ovulation induction, infertility, and ovarian cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10560672" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Risk of cancer after use of fertility drugs with in-vitro fertilisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620047" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cancer incidence in a cohort of infertile women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19037008" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cancer risk after exposure to treatments for ovulation induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051576" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172852" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ovarian cancer risk after the use of ovulation-stimulating drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302291" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ovarian cancer risk associated with varying causes of infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943232" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189051" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Infertility and risk of fatal ovarian cancer in a prospective cohort of US women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189051" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Infertility and risk of fatal ovarian cancer in a prospective cohort of US women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1476143" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561986" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10357995" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Fertility drugs and the risk of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557223" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Risk of breast cancer in a cohort of infertile women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151460" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cancer incidence following treatment for infertility at a clinic in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15217997" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Breast cancer risk associated with ovulation-stimulating drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15271872" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12749419" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17159014" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22773825" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Fertility drugs and young-onset breast cancer: results from the Two Sister Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27776142" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Menstrual and Reproductive Factors and Risk of Gastric and Colorectal Cancer in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359305" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21365647" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36041966" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk of colorectal cancer after use of fertility drugs-results from a large Danish population-based cohort of women with infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150258" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15066468" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Childhood tumor risk after treatment with ovulation-stimulating drugs.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
